AnaptysBio plans to release further data on rosnilimab and other pipeline assets in 2025, including studies for ulcerative colitis. These developments highlight AnaptysBio's ongoing efforts in ...

Stocks surged on Friday, with the S&P 500 soaring 2.13% as investors welcomed a break from tariff-driven turmoil. The market ...

indicating expedited progress in the company's clinical development pipeline. AnaptysBio announced an exclusive global license agreement with Vanda Pharmaceuticals for imsidolimab, which includes ...

Guggenheim raised the firm’s price target on AnaptysBio (ANAB ... by the company’s clinical development and the rest of its pipeline assets, pointing to a higher view on the odds of success ...

They have a few legacy molecules that they are not actively pursuing in their pipeline. These are ANB032 and Imsidolimab. They keep running these through trials and then dropping them from the ...

AltaGas Ltd (ALA.T) is expected to report $0.70 for 4Q. AnaptysBio Inc (ANAB) is expected to report $-1.62 for 4Q. Astria Therapeutics Inc (ATXS) is expected to report $-0.45 for 4Q. Biglari ...

The company had been nominally out in front among developers of Tim3-targeted drugs, slightly ahead of GSK and partner AnaptysBio with ... no longer appears in its pipeline listing.

AnaptysBio, Inc. (ANAB) shares rallied 9.5% in the last trading session to close at $18.71. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

AnaptysBio has a beta of 0.02, suggesting that its stock price is 98% less volatile than the S&P 500. Comparatively, Silo Pharma has a beta of 0.01, suggesting that its stock price is 99% less ...

(RTTNews) - AnaptysBio, Inc. (ANAB) on Monday announced that its Board of Directors has authorized a stock repurchase plan under which the company may repurchase up to $75 million of its ...